While most screening studies were limited to intermediate endpoints (eg, detection rates), Zahng et al. reported a reduction in liver cancer mortality by 40% for biannual serum alpha–fetoprotein testing in high risk groups (HBV infected or history of chronic hepatitis) after 5–10 screening rounds [56]. This evidence concerns the gene AFP and liver cancer.